Objective:To evaluate the efficacy and safety of oral oxymatrine preparation for the treatment of chronic hepatitis B(CHB).Methods:Randomized controlled trials(RCTs) on oral oxymatrine preparation in treating patients with CHB were retrieved until October 2013 by searching PubMed,the Cochrane Library,Embase and four Chinese databases,irrespective of language and publication status.Data extraction and data analyses were conducted according to the Cochrane standards.The risk of bias for each included trials and the quality of evidence on pre-specified outcomes were assessed.The RevMan software was used for statistical analyses.Results:Totally 52 RCTs enrolling 5,227 participants were included,of which 51 RCTs were included in meta-analyses.Oral oxymatrine preparation including oxymatrine capsule and oxymatrine tablet were associated with statistically significant effect on the clearance of hepatitis B virus(HBV) DNA,HBV surface antigen and HBV e antigen,and were beneficial to the normalization of serum alanine aminotransferase and aspartate aminotransferase.Nevertheless,the overall methodological quality and the quality of evidence in the included trials were poor.In addition,safety of oral oxymatrine preparation was not confirmed.Conclusions:Oral oxymatrine preparation showed some potential benefits for patients with CHB.However,the overall quality of evidence was limited and the safety of oral oxymatrine preparation for CHB patients was still unproven.More high quality evidence from rigorously designed RCTs is warranted to support the clinical use of oral oxymatrine preparation for patients with CHB. Objective: To evaluate the efficacy and safety of oral oxymatrine preparation for the treatment of chronic hepatitis B (CHB). Methods: Randomized controlled trials (RCTs) on oral oxymatrine preparation in treating patients with CHB was retrieved until October 2013 by searching PubMed, the Cochrane Library, Embase and four Chinese databases, irrespective of language and publication status. Data extraction and data analyzes were conducted according to the Cochrane standards. The risk of bias for each included trials and the quality of evidence on evidence-pre-specified outcomes were assessed. The RevMan software was used for statistical analyzes. Results: Totally 52 RCTs enrolling 5,227 participants were included, of which 51 RCTs were included in meta-analyzes. Oral oxymatrine preparation including oxymatrine capsule and oxymatrine tablet were associated with significant significant effect on the clearance of hepatitis B virus (HBV) DNA, HBV surface antigen and HBV e antigen, and were beneficial to the normali Yet, the overall methodological quality and the quality of evidence in the included trials were poor. addition, safety of oral oxymatrine preparation was not confirmed. Conclusions: Oral oxymatrine preparation showed some potential benefits for patients with CHB.However, the overall quality of evidence was limited and the safety of oral oxymatrine preparation for CHB patients was still unproven. More high quality evidence from rigorously designed RCTs is warranted to support the clinical use of oral oxymatrine preparation for patients with CHB.